This may be due to different chromatin states between DSRCT and prostate cancer cells, or could suggest a model in which AR binds to EWSR1::WT1, resulting in AR recruitment to WT1 binding sites (Fig. 3A). This evidence concerns the gene AR and prostate carcinoma.